Skip to content

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

About Us
Our Science
Pipeline
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs

News

Select Year
Clinical Trials
Search …

October 27, 2020

Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche’s Anti-PD-L1 Checkpoint Inhibitor

October 19, 2020

Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board

October 7, 2020

Oncolytics Biotech® to Participate in BIO Investor Forum Digital

September 1, 2020

Oncolytics Biotech® Announces Upcoming Presentations at Investor Conferences

August 26, 2020

Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

August 10, 2020

Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference

August 4, 2020

Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights

July 29, 2020

Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights

June 25, 2020

Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer

June 23, 2020

Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer

Page 20 of 71

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

Our Mission
Leadership
Board of Directors
Careers
Contact

Science

Our Science
Pipeline
Resources

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Manage Consent

Copyright © 2026 Oncolytics Biotech Inc.